

Melchior Seyfarth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10754893/publications.pdf>

Version: 2024-02-01

82
papers

12,552
citations

61687

45
h-index

71088

80
g-index

82
all docs

82
docs citations

82
times ranked

10668
citing authors

#	ARTICLE	IF	CITATIONS
1	Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock. The Cochrane Library, 2021, 2021, CD007398.	1.5	107
2	Extracorporeal life support in patients with acute myocardial infarction complicated by cardiogenic shock - Design and rationale of the ECLS-SHOCK trial. American Heart Journal, 2021, 234, 1-11.	1.2	88
3	Ten-Year Clinical Outcomes of Biodegradable Versus Durable Polymer New-Generation Drug-Eluting Stent in Patients With Coronary Artery Disease With and Without Diabetes Mellitus. Journal of the American Heart Association, 2021, 10, e020165.	1.6	5
4	Sex differences of resource utilisation and outcomes in patients with atrial arrhythmias and heart failure. Heart, 2020, 106, 527-533.	1.2	9
5	QTc evaluation in patients with bundle branch block. IJC Heart and Vasculature, 2020, 30, 100636.	0.6	11
6	<scp>QTc</scp> interval evaluation in patients with right bundle branch block or bifascicular blocks. Clinical Cardiology, 2020, 43, 957-962.	0.7	9
7	In-hospital mortality of patients with atrial arrhythmias: insights from the German-wide Helios hospital network of 161 502 patients and 34 025 arrhythmia-related procedures. European Heart Journal, 2018, 39, 3947-3957.	1.0	57
8	Applicability of a Novel Formula (Bogossian formula) for Evaluation of the QT Interval in Heart Failure and Left Bundle Branch Block Due to Right Ventricular Pacing. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 409-416.	0.5	12
9	Substantial improvement of primary cardiovascular prevention by a systematic score-based multimodal approach: A randomized trial: The PreFord-Study. European Journal of Preventive Cardiology, 2017, 24, 1544-1554.	0.8	22
10	Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. European Heart Journal, 2017, 38, 3523-3531.	1.0	280
11	Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump for Treating Cardiogenic Shock. Journal of the American College of Cardiology, 2017, 69, 358-360.	1.2	98
12	A new experimentally validated formula to calculate the QT interval in the presence of left bundle branch block holds true in the clinical setting. , 2017, 22, e12393.		21
13	Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents. Thrombosis and Haemostasis, 2017, 117, 1989-1999.	1.8	26
14	Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis. Scientific Reports, 2016, 6, 33054.	1.6	14
15	Single Center Retrospective Analysis of Conventional and Radial TIG Catheters for Transradial Diagnostic Coronary Angiography. Cardiology Research and Practice, 2015, 2015, 1-6.	0.5	6
16	ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. European Heart Journal, 2015, 36, 1252-1263.	1.0	366
17	Intraprocedural reduction of the veno-arterial norepinephrine gradient correlates with blood pressure response after renal denervation. EuroIntervention, 2015, 11, 824-834.	1.4	4
18	New formula for evaluation of the QT interval in patients with left bundle branch block. Heart Rhythm, 2014, 11, 2273-2277.	0.3	56

#	ARTICLE	IF	CITATIONS
19	Entanglement due to Delayed Removal of a Buddy Wire. <i>Case Reports in Cardiology</i> , 2014, 2014, 1-3.	0.1	1
20	Impact of Coronary Anatomy and Stenting Technique on Long-Term Outcome After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 29-36.	1.1	44
21	Zotarolimus- Versus Everolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2075-2082.	1.2	69
22	Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. <i>EMBO Molecular Medicine</i> , 2012, 4, 180-191.	3.3	298
23	Abciximab and Heparin versus Bivalirudin for Non-ST-Elevation Myocardial Infarction. <i>New England Journal of Medicine</i> , 2011, 365, 1980-1989.	13.9	285
24	Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock. , 2011, , CD007398.		28
25	Prognostic value of sensitive troponin T in patients with stable and unstable angina and undetectable conventional troponin. <i>American Heart Journal</i> , 2011, 161, 68-75.	1.2	90
26	Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. <i>Lancet, The</i> , 2011, 378, 1071-1078.	6.3	164
27	Sensitive troponin and N-terminal pro-brain natriuretic peptide in stable angina. <i>European Journal of Clinical Investigation</i> , 2011, 41, 1054-1062.	1.7	12
28	Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial. <i>Clinical Research in Cardiology</i> , 2011, 100, 579-585.	1.5	4
29	Impact of perfusion restoration at epicardial and tissue levels on markers of myocardial necrosis and clinical outcome of patients with acute myocardial infarction. <i>EuroIntervention</i> , 2011, 7, 128-135.	1.4	8
30	Impact of body mass index on clinical outcome in patients with acute coronary syndromes treated with percutaneous coronary intervention. <i>Heart and Vessels</i> , 2010, 25, 27-34.	0.5	23
31	Prognostic value of minimal blood flow restoration in patients with acute myocardial infarction after reperfusion therapy. <i>Clinical Research in Cardiology</i> , 2010, 99, 13-19.	1.5	10
32	One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial. <i>Clinical Research in Cardiology</i> , 2010, 99, 795-802.	1.5	22
33	Bleeding After Percutaneous Coronary Intervention With Bivalirudin or Unfractionated Heparin and One-Year Mortality. <i>American Journal of Cardiology</i> , 2010, 105, 163-167.	0.7	25
34	Predictive Factors and Impact of No Reflow After Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 27-33.	1.4	141
35	ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. <i>European Heart Journal</i> , 2010, 31, 2482-2491.	1.0	82
36	Patient-Specific Induced Pluripotent Stem-Cell Models for Long-QT Syndrome. <i>New England Journal of Medicine</i> , 2010, 363, 1397-1409.	13.9	1,132

#	ARTICLE	IF	CITATIONS
37	A Double-Blind, Randomized Study on Prevention and Existence of a Rebound Phenomenon of Platelets After Cessation of Clopidogrel Treatment. <i>Journal of the American College of Cardiology</i> , 2010, 55, 558-565.	1.2	55
38	5-Year Prognostic Value of No-Reflow Phenomenon After Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2383-2389.	1.2	380
39	2-Year Clinical and Angiographic Outcomes From a Randomized Trial of Polymer-Free Dual Drug-Eluting Stents Versus Polymer-Based Cypher and Endeavor, Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2536-2543.	1.2	108
40	Abciximab in Patients With Acute ST-Segmentâ€Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention After Clopidogrel Loading. <i>Circulation</i> , 2009, 119, 1933-1940.	1.6	300
41	Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. <i>European Heart Journal</i> , 2009, 30, 2441-2449.	1.0	207
42	Prognostic Value of Kidney Function in Patients With ST-Elevation and Nonâ€ST-Elevation Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention. <i>American Journal of Kidney Diseases</i> , 2009, 54, 830-839.	2.1	25
43	Paclitaxel- Versus Sirolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1760-1768.	1.2	180
44	Patterns of Presentation and Outcomes of Patients with Acute Coronary Syndromes. <i>Cardiology</i> , 2009, 113, 198-206.	0.6	36
45	Effect of Abciximab on Clinical and Angiographic Restenosis in Patients With Nonâ€ST-Segment Elevation Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2008, 101, 1226-1231.	0.7	5
46	Periprocedural Bleeding and 1-Year Outcome After Percutaneous Coronary Interventions. <i>Journal of the American College of Cardiology</i> , 2008, 51, 690-697.	1.2	452
47	Prognostic Significance of Epicardial Blood Flow Before and After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2008, 52, 512-517.	1.2	69
48	A Meta-Analysis of 17 Randomized Trials of a Percutaneous Coronary Intervention-Based Strategy in Patients With Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2008, 52, 894-904.	1.2	175
49	A Randomized Clinical Trial to Evaluate the Safety and Efficacy of a Percutaneous Left Ventricular Assist Device Versus Intra-Aortic Balloon Pumping for Treatment of Cardiogenic Shock Caused by Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1584-1588.	1.2	904
50	Impaired platelet function reduces myocardial infarct size in GÎ±q knock-out mice in vivo. <i>Journal of Molecular and Cellular Cardiology</i> , 2008, 44, 143-150.	0.9	16
51	One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. <i>European Heart Journal</i> , 2008, 29, 455-461.	1.0	55
52	Quantitative analysis of apoptotic markers in human endâ€stage heart failure. <i>European Journal of Heart Failure</i> , 2008, 10, 129-132.	2.9	13
53	A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. <i>European Heart Journal</i> , 2008, 30, 923-931.	1.0	123
54	Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention. <i>New England Journal of Medicine</i> , 2008, 359, 688-696.	13.9	323

#	ARTICLE	IF	CITATIONS
55	Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. <i>European Heart Journal</i> , 2007, 28, 2706-2713.	1.0	337
56	Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents. <i>New England Journal of Medicine</i> , 2007, 356, 1030-1039.	13.9	1,182
57	Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: Results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial. <i>American Heart Journal</i> , 2007, 154, 158.e1-158.e7.	1.2	21
58	Effectiveness of Drug-Eluting Stents in Patients With Bare-Metal In-Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2007, 49, 616-623.	1.2	149
59	Does Addition of Estradiol Improve the Efficacy of a Rapamycin-Eluting Stent?. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1265-1271.	1.2	34
60	Abciximab in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment<SUBTITLE>The ISAR-REACT 2 Randomized Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1531.	3.8	682
61	Age-Dependent Effect of Abciximab in Patients With Acute Coronary Syndromes Treated With Percutaneous Coronary Interventions. <i>Circulation</i> , 2006, 114, 2040-2046.	1.6	33
62	Gene transfer of the pancaspase inhibitor P35 reduces myocardial infarct size and improves cardiac function. <i>Journal of Molecular Medicine</i> , 2005, 83, 526-534.	1.7	15
63	Mechanical Reperfusion in Patients With Acute Myocardial Infarction Presenting More Than 12 Hours From Symptom Onset<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 2865.	3.8	238
64	Early Administration of Reteplase Plus Abciximab vs Abciximab Alone in Patients With Acute Myocardial Infarction Referred for Percutaneous Coronary Intervention<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 947.	3.8	149
65	A randomized trial comparing myocardial salvage achieved by coronary stenting versus balloon angioplasty in patients with acute myocardial infarction considered ineligible for reperfusion therapy. <i>Journal of the American College of Cardiology</i> , 2004, 43, 734-741.	1.2	57
66	A randomized trial of coronary stenting versus balloon angioplasty as a rescue intervention after failed thrombolysis in patients with acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004, 44, 2073-2079.	1.2	55
67	A randomized evaluation of the effects of glucose-insulin-potassium infusion on myocardial salvage in patients with acute myocardial infarction treated with reperfusion therapy. <i>American Heart Journal</i> , 2004, 148, 105.	1.2	44
68	Evaluation of Prolonged Antithrombotic Pretreatment ("Cooling-Off" Strategy) Before Intervention in Patients With Unstable Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 1593-9.	3.8	402
69	Essential myosin light chain as a target for caspase-3 in failing myocardium. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 11860-11865.	3.3	93
70	Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. <i>Lancet</i> , The, 2002, 359, 920-925.	6.3	195
71	Blocking Caspase-Activated Apoptosis Improves Contractility in Failing Myocardium. <i>Human Gene Therapy</i> , 2001, 12, 2051-2063.	1.4	89
72	Previous Cytomegalovirus Infection and Restenosis After Coronary Stent Placement. <i>Circulation</i> , 2001, 104, 1135-1139.	1.6	19

#	ARTICLE	IF	CITATIONS
73	Restenosis after coronary placement of various stent types. American Journal of Cardiology, 2001, 87, 34-39.	0.7	272
74	Comparison of effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent placement. American Journal of Cardiology, 2001, 87, 332-336.	0.7	54
75	Intracoronary Stenting and Angiographic Results. Circulation, 2001, 103, 2816-2821.	1.6	727
76	Previous Cytomegalovirus Infection and Risk of Coronary Thrombotic Events After Stent Placement. Circulation, 2000, 101, 11-13.	1.6	31
77	Enhanced Cardiac Contractility After Gene Transfer of V2 Vasopressin Receptors In Vivo by Ultrasound-Guided Injection or Transcoronary Delivery. Circulation, 2000, 101, 1578-1585.	1.6	69
78	Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. Journal of the American College of Cardiology, 2000, 35, 915-921.	1.2	334
79	Adenoviral Gene Transfer of the Human V2 Vasopressin Receptor Improves Contractile Force of Rat Cardiomyocytes. Circulation, 1999, 99, 925-933.	1.6	28
80	Pl ^A Polymorphism of Platelet Glycoprotein IIIa and Risk of Restenosis After Coronary Stent Placement. Circulation, 1999, 99, 1005-1010.	1.6	153
81	Transient Ischemia Reduces Norepinephrine Release During Sustained Ischemia. Circulation Research, 1996, 78, 573-580.	2.0	34
82	Recovery of stimulation-evoked noradrenaline release during reperfusion after acute ischemia in rat hearts. Journal of Molecular and Cellular Cardiology, 1992, 24, S17.	0.9	1